Gelesis Holdings Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Gelesis Holdings.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	27.1%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

Apr 19

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Gelesis Holdings yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:GLSH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2023	12	-52	-50	-46	N/A
3/31/2023	20	-57	-59	-51	N/A
12/31/2022	26	-95	-87	-78	N/A
9/30/2022	26	-45	-100	-90	N/A
6/30/2022	22	-85	-75	-60	N/A
3/31/2022	16	-179	-98	-82	N/A
12/31/2021	11	-188	-75	-55	N/A
9/30/2021	10	-232	-57	-30	N/A
6/30/2021	8	-195	-84	-52	N/A
3/31/2021	25	-79	-57	-21	N/A
12/31/2020	21	-38	-54	-22	N/A
12/31/2019	N/A	-13	-39	-24	N/A
12/31/2014	0	-18	N/A	-4	N/A
9/30/2014	1	-15	N/A	-3	N/A
12/31/2013	6	N/A	N/A	-4	N/A
12/31/2012	4	-3	N/A	3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if GLSH's forecast earnings growth is above the savings rate (2.2%).

Kazançlar ve Piyasa: Insufficient data to determine if GLSH's earnings are forecast to grow faster than the US market

Yüksek Büyüme Kazançları: Insufficient data to determine if GLSH's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if GLSH's revenue is forecast to grow faster than the US market.

Yüksek Büyüme Geliri: Insufficient data to determine if GLSH's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if GLSH's Return on Equity is forecast to be high in 3 years time

Gelesis Holdings Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Gelesis Holdings, Inc. Reiterates Earnings Guidance for the Full Year Fiscal Year 2022

Gelesis Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Recent updates

Motion for Joint Administration Approved for Gelesis Holdings, Inc.

Gelesis Holdings, Inc. Filed for Bankruptcy

Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer

Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023

Full year 2022 earnings released: US$1.35 loss per share (vs US$32.89 loss in FY 2021)

KLP Enterprises Engages in Discussions with Gelesis Holdings

Gelesis Holdings Receives a Notification Letter from the New York Stock Exchange

Gelesis Holdings Receives Notice of NYSE Market Capitalization Listing Rule Non-Compliance

Third quarter 2022 earnings released: US$0.20 loss per share (vs US$9.61 loss in 3Q 2021)

Gelesis Holdings, Inc. Reiterates Earnings Guidance for the Full Year Fiscal Year 2022

Gelesis Holdings GAAP EPS of -$0.20, revenue of $6.65M

Gelesis Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Gelesis Holdings Receives Notice of NYSE Trading Share Price Listing Rule Non-Compliance

Gelesis receives NYSE notice of non-compliance

Gelesis Holdings, Inc. to Present Data from the Light Up Study with Gelesis' Oral Hydrogel Treatment Gs200 at Obesity Week

David Abraham Ceases to Serve as General Counsel, Chief Compliance Officer and Corporate Secretary of Gelesis Holdings, Inc

Gelesis Holdings Inc. Presents Clinical Data from the Light-Up Study At the International Congress of Endocrinology

Second quarter 2022 earnings released

Gelesis Holdings, Inc. Provides Revenue Guidance for the Full Year 2022

Gelesis Holdings GAAP EPS of -$0.17, revenue of $8.97M; narrows FY22 guidance

Gelesis Holdings, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Gelesis Holdings, Inc. to Report Q1, 2022 Results on May 12, 2022

Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022

Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

Gelesis Holdings, Inc. announced delayed annual 10-K filing

Gelesis Holdings, Inc. Provides Revenue Guidance for the Year 2022

Director recently bought US$100k worth of stock

No independent directors

Gelesis, Inc. completed the acquisition of Capstar Special Purpose Acquisition Corp. (NYSE:CPSR) from a group of shareholders in a reverse merger transaction.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin